A UBC-led team has received more than $23 million in federal funding to develop precision radiopharmaceuticals that promise to transform cancer treatment in Canada and beyond.
Radiation has been a staple of cancer treatment for decades, with approximately 50 per cent of cancer patients receiving radiation therapy at some point in their journey.
While effective, traditional radiation therapies rely on intense beams of energy shot from outside the body. These beams can kill cancer, but their use is limited to select locations, making them less suited for difficult-to-treat metastatic cancers that have spread to multiple sites.
Now, a UBC-led team of Canadian researchers has received $23.7 million in federal funding to develop a new generation of radiation therapy, known as radiopharmaceutical therapy, that delivers highly targeted doses of radiation from within.
Read more at University of British Columbia
Image: A radiochemistry processing hot cell at TRIUMF. (Credit: TRIUMF)